{
    "clinical_study": {
        "@rank": "151253", 
        "acronym": "TOGA", 
        "arm_group": [
            {
                "arm_group_label": "ORACEA\u00ae", 
                "arm_group_type": "Experimental", 
                "description": "40mg doxycycline"
            }, 
            {
                "arm_group_label": "Placebo", 
                "arm_group_type": "Placebo Comparator"
            }
        ], 
        "brief_summary": {
            "textblock": "This is a prospective, randomized study to evaluate the efficacy and safety of ORACEA\u00ae in\n      the treatment of geographic atrophy due to dry age-related macular degeneration (AMD)."
        }, 
        "brief_title": "Clinical Study to Evaluate Treatment With ORACEA\u00ae for Geographic Atrophy (TOGA)", 
        "completion_date": {
            "#text": "December 2017", 
            "@type": "Anticipated"
        }, 
        "condition": "Geographic Atrophy", 
        "condition_browse": {
            "mesh_term": [
                "Macular Degeneration", 
                "Geographic Atrophy", 
                "Atrophy"
            ]
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Male or female, age 55 - 85.\n\n          -  Best corrected visual acuity of 20/20 - 20/400 in the study eye\n\n          -  Best corrected visual acuity of hand motion or better in the non-study eye\n\n          -  Clinical diagnosis of geographic atrophy secondary to non-exudative age-related\n             macular degeneration in at least one eye (study eye)\n\n          -  Geographic atrophy lesions of \u2265 0.5 and \u2264 7.0 MPS disc areas\n\n        Exclusion Criteria:\n\n          -  History of or active presence of choroidal neovascularization secondary to exudative\n             age-related macular degeneration in the study eye\n\n          -  History of or active presence of choroidal neovascularization secondary to exudative\n             age-related macular degeneration in the non-study eye requiring any treatment within\n             12 months prior to Day 0 or expected to require treatment for the duration of the\n             study\n\n          -  Prior treatment for non-exudative age-related  macular degeneration\n\n          -  Current or previous history of treatment of the study eye with any tetracycline\n             derivative for any ocular condition.\n\n          -  History of vitreoretinal surgery, corneal transplant, or laser photocoagulation in\n             the study eye\n\n          -  Any intraocular or periocular surgery within 90 days prior to Day 0 in the study eye.\n\n          -  History of any hypersensitivity to tetracycline components\n\n          -  Use of a tetracycline derivative therapy for a concurrent systemic or ocular disorder\n             within 90 days of Day 0\n\n          -  History of sensitivity to the sun"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "85 Years", 
            "minimum_age": "55 Years"
        }, 
        "enrollment": {
            "#text": "286", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "January 31, 2013", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01782989", 
            "org_study_id": "16586"
        }, 
        "intervention": [
            {
                "arm_group_label": "ORACEA\u00ae", 
                "description": "ORACEA\u00ae (40mg doxycycline) capsule daily for 24 months", 
                "intervention_name": "ORACEA\u00ae", 
                "intervention_type": "Drug"
            }, 
            {
                "arm_group_label": "Placebo", 
                "description": "Placebo capsule daily for 24 months", 
                "intervention_name": "Placebo", 
                "intervention_type": "Drug"
            }
        ], 
        "intervention_browse": {
            "mesh_term": [
                "Doxycycline", 
                "Doxycycline hyclate"
            ]
        }, 
        "is_fda_regulated": "Yes", 
        "is_section_801": "Yes", 
        "keyword": [
            "geographic atrophy", 
            "non-exudative age-related macular degeneration", 
            "macular degeneration", 
            "dry macular degeneration", 
            "dry AMD"
        ], 
        "lastchanged_date": "February 6, 2013", 
        "location": {
            "contact": {
                "email": "klh7v@virginia.edu", 
                "last_name": "Kristina Holbrook", 
                "phone": "434-243-2852"
            }, 
            "facility": {
                "address": {
                    "city": "Charlottesville", 
                    "country": "United States", 
                    "state": "Virginia", 
                    "zip": "22903"
                }, 
                "name": "University of Virginia"
            }, 
            "investigator": {
                "last_name": "Paul Yates, MD, PhD", 
                "role": "Principal Investigator"
            }, 
            "status": "Not yet recruiting"
        }, 
        "location_countries": {
            "country": "United States"
        }, 
        "number_of_arms": "2", 
        "official_title": "A Randomized, Double Blind, Placebo Controlled Study Evaluating ORACEA\u00ae in Subjects With Geographic Atrophy Secondary to Non-Exudative Age-Related Macular Degeneration", 
        "overall_contact": {
            "email": "klh7v@virginia.edu", 
            "last_name": "Paul Yates, MD, PhD", 
            "phone": "434-243-2852"
        }, 
        "overall_official": {
            "affiliation": "University of Virginia", 
            "last_name": "Paul A Yates, MD, PhD", 
            "role": "Principal Investigator"
        }, 
        "overall_status": "Not yet recruiting", 
        "oversight_info": {
            "authority": "United States: Food and Drug Administration", 
            "has_dmc": "Yes"
        }, 
        "phase": "Phase 2/Phase 3", 
        "primary_completion_date": {
            "#text": "March 2017", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "measure": "Rate of enlargement in area of geographic atrophy in the study eye during the treatment period.", 
            "safety_issue": "No", 
            "time_frame": "Month 6 and Month 30"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01782989"
        }, 
        "responsible_party": {
            "investigator_affiliation": "University of Virginia", 
            "investigator_full_name": "Paul Yates, MD, PhD", 
            "investigator_title": "Assistant Professor of Ophthalmology", 
            "responsible_party_type": "Sponsor-Investigator"
        }, 
        "secondary_outcome": {
            "measure": "Change in Best Corrected Visual Acuity (BCVA)", 
            "safety_issue": "No", 
            "time_frame": "Month 6 and Month 30"
        }, 
        "source": "University of Virginia", 
        "sponsors": {
            "collaborator": {
                "agency": "MEDARVA Foundation", 
                "agency_class": "Other"
            }, 
            "lead_sponsor": {
                "agency": "Paul Yates, MD, PhD", 
                "agency_class": "Other"
            }
        }, 
        "start_date": "February 2013", 
        "study_design": "Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "February 2013"
    }
}